Home › Compare › DMPLF vs ABBV
DMPLF yields 0.59% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, DMPLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DMPLF + ABBV for your $10,000?
Del Monte Pacific Limited, an investment holding company, manufactures, processes, markets, and distributes food, beverages, and other related products in the Americas, the Asia Pacific, and Europe. The company is involved in growing, processing, and selling packaged fruit and vegetable products, including canned and fresh pineapples, and tropical mixed fruits, as well as canned beans, peaches, and corns; juices, juice drinks, and pineapple juice concentrates; fresh fruits; and tomato-based products, such as ketchup, tomato sauce, pasta sauce, recipe sauce, pizza sauce, pasta, broth, and condiments. It offers its products under the Del Monte, S&W, Today's, Contadina, and College Inn brand names. The company also produces and distributes private label food products, as well as offers UHP avocado and processed refrigerated fruit products; and provides administrative support and liaison services. In addition, it offers licensing, management, logistics, and marketing and support services, as well as holds real estate properties. The company was founded in 1886 and is based in Road Town, British Virgin Islands. Del Monte Pacific Limited is a subsidiary of NutriAsia Pacific Limited.
Full DMPLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.